๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Weekly epirubicin in patients with hormone-resistant prostate cancer

โœ Scribed by Petrioli, R; Fiaschi, A I; Pozzessere, D; Messinese, S; Sabatino, M; Marsili, S; Correale, P; Manganelli, A; Salvestrini, F; Francini, G

Book ID
109997357
Publisher
Nature Publishing Group
Year
2002
Tongue
English
Weight
115 KB
Volume
87
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Suramin in combination with weekly epiru
Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma
โœ Alfredo Falcone; Andrea Antonuzzo; Romano Danesi; Giacomo Allegrini; Lencioni Mo ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 97 KB ๐Ÿ‘ 2 views

## BACKGROUND. Suramin and epirubicin are both active agents in the treatment of patients with hormone-refractory advanced prostate carcinoma, with demonstrated antitumor synergism in vitro on human prostate carcinoma cells and different dose-limiting toxicities. The authors conducted this Phase I

Liarozole (R75251) in hormone-resistant
Liarozole (R75251) in hormone-resistant prostate cancer patients
โœ Dijkman, G.A.; Fernandez del Moral, P.; Bruynseels, J.; De Porre, P.; Denis, L.; ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 40 KB

## Background: Liarozole is an imidazole derivative that has been identified as an inhibitor of the cytochrome p450-dependent all-trans retinoid acid (ra) breakdown. ra is one of the principal endogenous compounds that controls growth and differentiation of epithelial tissues in mammals. ## Method

Hormone Resistance in Prostate Cancer
Hormone Resistance in Prostate Cancer
โœ Mary Josephine P. Pilat; Jeffery M. Kamradt; Kenneth J. Pienta ๐Ÿ“‚ Article ๐Ÿ“… 1998 ๐Ÿ› Springer ๐ŸŒ English โš– 56 KB